<  Back to the Polytechnique Montréal portal

Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria

Neda Moradin, Sabrina Torre, Susan Gauthier, Mifong Tam, Jalal Hawari, Kirsten Vandercruyssen, Bart De Spiegeleer, Anny Fortin, Mary M. Stevenson and Philippe Gros

Article (2016)

Published Version
Terms of Use: Creative Commons Attribution .
Download (1MB)
Cite this document: Moradin, N., Torre, S., Gauthier, S., Tam, M., Hawari, J., Vandercruyssen, K., ... Gros, P. (2016). Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria. Malaria Journal, 15, p. 1-12. doi:10.1186/s12936-016-1317-3
Show abstract Hide abstract


Background: The potential emergence and spread of resistance to artemisinins in the Plasmodium falciparum malaria parasite constitutes a major global health threat. Hence, improving the efficacy of artemisinins and of artemisinin-based combination therapy (ACT) represents a major short-term goal in the global fight against malaria. Mice defective in the enzyme pantetheinase (Vnn3) show increased susceptibility to blood-stage malaria (increased parasitaemia, reduced survival), and supplementation of Vnn3 mutants with the reaction product of pantetheinase, cysteamine, corrects in part the malaria-susceptibility phenotype of the mutants. Cysteamine (Cys) is a small, naturally occurring amino-thiol that has very low toxicity in vivo and is approved for clinical use in the life-long treatment of the kidney disorder nephropathic cystinosis.Methods: The ability of Cys to improve the anti-plasmodial activity of different clinically used artemisinins was tested. The effect of different CYS/ART combinations on malarial phenotypes (parasite blood-stage replication, overall and survival from lethal infection) was assessed in a series of in vivo experiments using Plasmodium strains that induce either blood-stage (Plasmodium chabaudi AS) or cerebral disease (Plasmodium berghei ANKA). This was also evaluated in an ex vivo experimental protocol that directly assesses the effect of such drug combinations on the viability of Plasmodium parasites, as measured by the ability of tested parasites to induce a productive infection in vivo in otherwise naive animals.Results: Cys is found to potentiate the anti-plasmodial activity of artesunate, artemether, and arteether, towards the blood-stage malaria parasite P. chabaudi AS. Ex vivo experiments, indicate that potentiation of the anti-plasmodial activity of artemisinins by Cys is direct and does not require the presence of host factors. In addition, potentiation occurs at sub-optimal concentrations of artemisinins and Cys that on their own have little or no effect on parasite growth. Cys also dramatically enhances the efficacy and protective effect of artemisinins against cerebral malaria induced by infection with the P. berghei ANKA parasite.Conclusion: These findings indicate that inclusion of Cys in current formulations of ACT, or its use as adjunct therapy could improve the anti-plasmodial activity of artemisinin, decrease mortality in cerebral malaria patients, and prevent or delay the development and spread of artemisinin resistance.

Uncontrolled Keywords

Artemisinins; Blood-stage malaria; Cerebral malaria; Cysteamine; Drug resistance; Plasmodium; Animals; Antimalarials; Artemisinins; Cell Survival; Cysteamine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Malaria; Malaria, Cerebral; Mice; Plasmodium berghei; Plasmodium chabaudi; Survival Analysis; Treatment Outcome; Antimalarials; Artemisinins; Cysteamine

Open Access document in PolyPublie
Subjects: 9000 Sciences de la santé > 9000 Sciences de la santé
Department: Département des génies civil, géologique et des mines
Research Center: Non applicable
Funders: Canadian Institutes of Health Research, Raptor Pharmaceuticals
Date Deposited: 09 Jan 2019 12:35
Last Modified: 08 Apr 2021 10:43
PolyPublie URL: https://publications.polymtl.ca/3508/
Document issued by the official publisher
Journal Title: Malaria Journal (vol. 15)
Publisher: BioMed Central
Official URL: https://doi.org/10.1186/s12936-016-1317-3


Total downloads

Downloads per month in the last year

Origin of downloads


Repository Staff Only